Clinical Scoring Tools. Which Is Best to Predict Clinical Response and Long-Term Outcomes?

Infectious Disease Clinics of North America

Volumn 27, Issue 1, 2013, Pages 33-48

  Wiemken, Timothy ^a   Kelley, Robert ^a   Ramirez, Julio ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Mortality; Outcomes; Pneumonia; Prediction scores; Severity scores; Site of care

Indexed keywords

ANTIBIOTIC AGENT;

CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA SEVERITY INDEX; PREDICTION; PREDICTIVE VALUE; QUALITY OF LIFE; REVIEW; SCORING SYSTEM;

COMMUNITY-ACQUIRED INFECTIONS; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; PNEUMONIA; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84873554933     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2012.11.015     Document Type: Review

References (49)

1. Fine M.J., Hough L.J., Medsger A.R., et al. The hospital admission decision for patients with community-acquired pneumonia. Results from the pneumonia patient outcomes research team cohort study. Arch Intern Med 1997, 157(1):36-44.
2. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336(4):243-250.
3. Lim W.S., van der Eerden M.M., Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58(5):377-382.
4. Charles P.G., Wolfe R., Whitby M., et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008, 47(3):375-384.
5. Espana P.P., Capelastegui A., Gorordo I., et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med 2006, 174(11):1249-1256.
6. Aliberti S., Amir A., Peyrani P., et al. Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest 2008, 134(5):955-962.
7. Hoogewerf M., Oosterheert J.J., Hak E., et al. Prognostic factors for early clinical failure in patients with severe community-acquired pneumonia. Clin Microbiol Infect 2006, 12(11):1097-1104.
8. Roson B., Carratala J., Fernandez-Sabe N., et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004, 164(5):502-508.
9. Menendez R., Torres A., Zalacain R., et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004, 59(11):960-965.
10. Genne D., Sommer R., Kaiser L., et al. Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2006, 25(3):159-166.
11. Genne D., Kaiser L., Kinge T.N., et al. Community-acquired pneumonia: causes of treatment failure in patients enrolled in clinical trials. Clin Microbiol Infect 2003, 9(9):949-954.
12. Arancibia F., Ewig S., Martinez J.A., et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000, 162(1):154-160.
13. Aliberti S., Blasi F. Clinical stability versus clinical failure in patients with community-acquired pneumonia. Semin Respir Crit Care Med 2012, 33(3):284-291.
14. Yandiola P.P., Capelastegui A., Quintana J., et al. Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. Chest 2009, 135(6):1572-1579.
15. Ramirez J.A. Fostering international multicenter collaborative research: the CAPO Project. Int J Tuberc Lung Dis 2007, 11(10):1062-1065.
16. Ramirez J.A. Worldwide perspective of the quality of care provided to hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study. Semin Respir Crit Care Med 2005, 26(6):543-552.
17. Fukuyama H., Ishida T., Tachibana H., et al. Validation of scoring systems for predicting severe community-acquired pneumonia. Intern Med 2011, 50(18):1917-1922.
18. Labarere J., Schuetz P., Renaud B., et al. Acad Emerg Med 2012, 19(9):993-1003. [in Spanish].
19. Marti C., Garin N., Grosgurin O., et al. Prediction of severe community acquired pneumonia: a systematic review and meta-analysis. Crit Care 2012, 16(4):R141.
20. Ewig S., Bauer T., Richter K., et al. Prediction of in-hospital death from community-acquired pneumonia by varying CRB-age groups. Eur Respir J 2012, [Epub ahead of print].
21. Richards G., Levy H., Laterre P.F., et al. CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS. J Intensive Care Med 2011, 26(1):34-40.
22. Karmakar G., Wilsher M. Use of the 'CURB 65' score in hospital practice. Intern Med J 2010, 40(12):828-832.
23. Riquelme R., Jimenez P., Videla A.J., et al. Predicting mortality in hospitalized patients with 2009 H1N1 influenza pneumonia. Int J Tuberc Lung Dis 2011, 15(4):542-546.
24. Ahkee S., Smith S., Newman D., et al. Early switch from intravenous to oral antibiotics in hospitalized patients with infections: a 6-month prospective study. Pharmacotherapy 1997, 17(3):569-575.
25. Ramirez J.A., Srinath L., Ahkee S., et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995, 155(12):1273-1276.
26. Niederman M.S., Mandell L.A., Anzueto A., et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163(7):1730-1754.
27. Halm E.A., Fine M.J., Marrie T.J., et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998, 279(18):1452-1457.
28. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-S72.
29. Arnold F., LaJoie A., Marrie T., et al. The pneumonia severity index predicts time to clinical stability in patients with community-acquired pneumonia. Int J Tuberc Lung Dis 2006, 10(7):739-743.
30. Arnold F.W., Brock G.N., Peyrani P., et al. Predictive accuracy of the pneumonia severity index vs CRB-65 for time to clinical stability: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respir Med 2010, 104(11):1736-1743.
31. Menendez R., Torres A., Rodriguez de Castro F., et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004, 39(12):1783-1790.
32. Salomoni G, Aliberti S, Travierso C. Incidence, risk factors and outcomes of nonresolving pneumonia. Presented at the European Respiratory Society Annual Congress. Barcelona, September 18-22, 2010.
33. Kyprianou A., Hall C.S., Shah R., et al. The challenge of nonresolving pneumonia. Knowing the norms of radiographic resolution is key. Postgrad Med 2003, 113(1):79-82.
34. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30(6):473-483.
35. El Moussaoui R., Opmeer B.C., de Borgie C.A., et al. Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia. Chest 2006, 130(4):1165-1172.
36. Medicare Payment Advisory Commission A path to bundled payment around a rehospitalization. A report to the congress: reforming the delivery system 2005, 83-103. Medicare Payment Advisory Commission, Washington, DC, Available at:. http://www.medpac.gov/documents/Jun08_EntireReport.pdf, Commission MPA (Ed.).
37. Jencks S.F., Williams M.V., Coleman E.A. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 2009, 360(14):1418-1428.
38. Mortensen E.M., Coley C.M., Singer D.E., et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002, 162(9):1059-1064.
39. Mortensen E.M., Kapoor W.N., Chang C.C., et al. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis 2003, 37(12):1617-1624.
40. Chalmers J.D., Mandal P., Singanayagam A., et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med 2011, 37(9):1409-1420.
41. Flanders W.D., Tucker G., Krishnadasan A., et al. Validation of the pneumonia severity index. Importance of study-specific recalibration. J Gen Intern Med 1999, 14(6):333-340.
42. Lettinga K.D., Verbon A., Nieuwkerk P.T., et al. Health-related quality of life and posttraumatic stress disorder among survivors of an outbreak of Legionnaires disease. Clin Infect Dis 2002, 35(1):11-17.
43. Bordon J., Wiemken T., Peyrani P., et al. Decrease in long-term survival for hospitalized patients with community-acquired pneumonia. Chest 2010, 138(2):279-283.
44. Kaplan V., Clermont G., Griffin M.F., et al. Pneumonia: still the old man's friend?. Arch Intern Med 2003, 163(3):317-323.
45. Koivula I., Sten M., Makela P.H. Prognosis after community-acquired pneumonia in the elderly: a population-based 12-year follow-up study. Arch Intern Med 1999, 159(14):1550-1555.
46. Waterer G.W., Kessler L.A., Wunderink R.G. Medium-term survival after hospitalization with community-acquired pneumonia. Am J Respir Crit Care Med 2004, 169(8):910-914.
47. Courtais C., Kuster N., Dupuy A.M., et al. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia. Am J Emerg Med 2012, 10.1016/j.ajem.2012.07.017.
48. Espana P.P., Capelastegui A., Bilbao A., et al. Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2012, 31(12):3397-3405.
49. Kolditz M., Ewig S., Hoffken G. Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. Eur Respir J 2012, [Epub ahead of print].